Small molecule antagonists of bacterial quorum-sensing receptors
A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.
1. A small molecule characterized by its ability to bind to a Gram-negative bacterial LuxN receptor at the autoinducer-1 (AI-1) binding site of LuxN, wherein said small molecule is represented by the formula:
wherein X is O or S; n is 0, 1 or 2; Y is O, S or CH 2 ;
wherein the aryl ring substituent Z represents single or multiple substituents, wherein when Z represents a single substituent Z is located at the ortho, meta or para position, when Z represents multiple substituents, the substituents are located at any combination of the ortho, meta or para positions, and wherein Z is selected from the group consisting of halogen, hydroxyl, alkoxyl, cyano, nitro, amido, acetamido, amino, alkylamino, aryl, heteroaryl, acyl, alkyl, cycloalkyl, sulfonamide, and alkyl sulfonamide.
2. The small molecule of claim 1 wherein X is S and n is 1, the small molecule being represented by the formula:
wherein R is any of the structures:
3. The small molecule of claim 1 wherein X is O and n is 1, that is represented by the formula:
4. The small molecule of claim 2 wherein the Gram-negative bacterial LuxN receptor is from Vibrio harveyi.
5. The small molecule of claim 2 further characterized by its ability to bind to a Gram-negative bacterial LuxR type receptor.
6. The small molecule of claim 5 wherein the Gram-negative bacterial LuxR type receptor is Chromobacterium violaceum CviR.
7. A method of disrupting detection of acyl-homoserine lactone-type autoinducer in Gram-negative bacteria comprising contacting the bacteria with the compound of claim 2 .
8. A pharmaceutical composition comprising one or more small molecules as recited in claim 2 and a pharmaceutically acceptable carrier, excipient or diluent.
9. A bacterial biofilm-inhibiting composition comprising one or more small molecules as recited in claim 2 and a solvent.
10. The composition of claim 9 wherein the solvent is DMSO.
11. A method of treating a bacterial infection of Gram-negative bacteria, comprising administering to a subject in need a therapeutically effective amount of a small molecule of claim 2 , wherein the bacteria is of a type that controls virulence factors by quorum sensing.
12. A method of controlling growth of quorum sensing Gram-negative bacteria attached to a solid surface, comprising exposing the bacteria to a composition comprising one or more compounds as recited in claim 2 , in an amount that affects biofilm formation.
13. A method of controlling virulence factor expression in Gram-negative bacteria comprising contacting the bacteria with a composition comprising one or more compounds as recited in claim 2 .
14. A method of preventing biofilm formation comprising administering the small molecule recited in claim 2 to a surface.
15. The method of claim 14 wherein the surface is a solid material.
16. A method of inhibiting quorum sensing-mediated activity in Gram-negative bacteria comprising contacting the bacteria with the compound as recited in claim 2 .
17. The method of claim 16 wherein the activity is pathogenicity.
18. The method of claim 17 wherein the bacterial species is selected from the group consisting of V. harveyi and C. violaceum.
19. The method of claim 17 wherein the bacterial species is C. violaceum.
20. The method of claim 17 wherein the bacteria are pathogenic to humans or animals.
21. The method of claim 17 wherein the bacteria are pathogenic to plants.
22. The method of claim 17 wherein the bacteria are pathogenic to marine life.
23. The method of claim 16 wherein the activity is bioluminescence, siderophore production, type III secretion, or metalloprotease production.
24. A method of inhibiting bacterial infection of a host comprising contacting the bacteria with the compound as recited in claim 2 , wherein the bacteria are Gram-negative quorum sensing bacteria.